MATCH Treatment Subprotocol Z1H: Phase 2 STudy of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC
(See required screening study ECOG-ACRIN EAY131)
Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.
The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, firstname.lastname@example.org or 406-969-6067, for the consent & for any questions.
Effective today, January 8th, 2020, EAY131 (MATCH) Subprotocol Z1H-Phase II is suspended and no new patients will be assigned to this treatment arm. Patients who are currently being treated on this subprotocol will continue on the study with no changes in their participation.